{"filings":[{"id":2226357,"accession_number":"0001193125-26-347907","cik":1840229,"company_name":"MiNK Therapeutics, Inc.","ticker":"INKT","form_type":"8-K","filed_at":"2026-08-13T11:40:44+00:00","items":["2.02","9.01"],"status":"ready","headline":"MiNK Q2 2026 net loss $3.1M, cash $8.8M; Phase 2 ALI data positive","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $3.1M ($0.62/share) vs $4.2M ($1.06) in Q2 2025; six-month loss $5.9M vs $7.0M.","Cash $8.8M at June 30, 2026, down from $9.5M at March 31 and $13.4M at Dec 31, 2025.","Randomized Phase 2 (C-1300-02) in acute lung injury: first patients alive at Day 28, improved oxygenation, infection control, ventilator/vasopressor liberation; no major SAEs.","Established first paid international named-patient access program in Brazil via Orphan Drug Consulting for agenT-797.","Data presented at MHSRS; U.S. expansion underway, more data expected early 2027."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":56843466.67092338,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1207796,"accession_number":"0001193125-26-278642","cik":1840229,"company_name":"MiNK Therapeutics, Inc.","ticker":"INKT","form_type":"8-K","filed_at":"2026-06-23T14:09:39+00:00","items":["5.07"],"status":"ready","headline":"MiNK Therapeutics stockholders re-elect Garo Armen, Barbara Ryan, John Holcomb as directors; ratify KPMG","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Quorum of 3,277,906 shares (65.79% of outstanding) present at annual meeting.","All three Class II director nominees elected: Garo Armen (2,363,360 for), Barbara Ryan (2,362,760 for), John Holcomb (2,381,491 for).","Ratification of KPMG as independent auditor for 2026 approved: 3,249,124 for, 26,560 against, 2,222 abstain.","Broker non-votes of 881,648 on director election; no broker non-votes on auditor ratification."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":56843466.67092338,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":452716,"accession_number":"0001193125-26-225369","cik":1840229,"company_name":"MiNK Therapeutics, Inc.","ticker":"INKT","form_type":"8-K","filed_at":"2026-05-15T12:03:20+00:00","items":["2.02","9.01"],"status":"ready","headline":"MiNK Q1 cash $9.5M, net loss $2.7M; initiates randomized Phase 2 for agenT-797 in ARDS","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash $9.5M at Mar 31 (down from $13.4M at Dec 31); repaid $5.2M Agenus convertible note.","Net loss $2.7M ($0.57/sh) vs $2.8M ($0.70/sh) year ago; raised $3.0M via ATM in Q1.","Initiated randomized Phase 2 trial of agenT-797 in severe acute lung injury/ARDS; data expected H2 2026.","Non-dilutive C-Further collaboration provides up to $1.1M for PRAME-targeted iNKT therapy in pediatric cancers.","Upcoming ATS presentation May 20 on agenT-797 for coccidioides infection; NIH-funded GvHD program ongoing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":56843466.67092338,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":109669,"accession_number":"0001193125-26-133346","cik":1840229,"company_name":"MiNK Therapeutics, Inc.","ticker":"INKT","form_type":"8-K","filed_at":"2026-03-31T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"MiNK Therapeutics reports FY2025 net loss $12.5M; ARDS Phase 2 trial initiation in 1H 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss FY2025 $12.5M ($2.93/sh) vs $10.8M ($2.86/sh) in FY2024; cash $13.4M at year end, plus $3.0M raised since.","Phase 2 trial for agenT-797 in ARDS/hypoxemic pneumonia to initiate 1H 2026; early data by year end.","GVHD program funded by NIH STTR grant and Mary Gooze award; trial launch May 2026, preliminary data 2H 2026.","C-Further collaboration provides up to $1.1M non-dilutive funding for PRAME-TCR iNKT in pediatric oncology.","Appointments: Dr. Terese Hammond as Head of Pulmonary; Melissa Orilall as Principal Financial Officer."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":56843466.67092338,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":109668,"accession_number":"0001193125-26-127931","cik":1840229,"company_name":"MiNK Therapeutics, Inc.","ticker":"INKT","form_type":"8-K","filed_at":"2026-03-27T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"MiNK Therapeutics confirms active discussions for combination trials and strategic investments","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Company is in active discussions with multiple parties for potential combination trials of agenT-797.","Discussions also include potential strategic minority investments in MiNK.","No binding arrangements have been publicly disclosed; no assurance of final agreements.","Clarification issued in response to third-party postings regarding potential trials."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":56843466.67092338,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":109667,"accession_number":"0001193125-26-116219","cik":1840229,"company_name":"MiNK Therapeutics, Inc.","ticker":"INKT","form_type":"8-K","filed_at":"2026-03-19T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"MiNK Therapeutics appoints new Principal Financial Officer and Principal Accounting Officer","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Melissa Orilall, VP Global Financial Operations at Agenus, appointed Principal Financial Officer effective March 13, 2026.","Austin Charette, Senior Director Financial Reporting & Compliance at Agenus, appointed Principal Accounting Officer effective same date.","Both provide services via Amended Intercompany Services Agreement with Agenus; no direct compensation from MiNK.","No new arrangements or modifications tied to these designations."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":56843466.67092338,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":109666,"accession_number":"0001193125-26-000916","cik":1840229,"company_name":"MiNK Therapeutics, Inc.","ticker":"INKT","form_type":"8-K","filed_at":"2026-01-02T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Director Robert Kadlec resigns from MiNK Therapeutics board for U.S. government role","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Robert Kadlec, MD, resigned from the Board of Directors effective December 29, 2025.","Resignation due to acceptance of senior public service role as Assistant Secretary of War for Nuclear Deterrence and Chemical and Biological Defense Policy and Programs.","Dr. Kadlec joined the Board in October 2024; no replacement announced.","Company expressed appreciation for his service and perspective."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":56843466.67092338,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":126197,"accession_number":"0001193125-25-311229","cik":1840229,"company_name":"MiNK Therapeutics, Inc.","ticker":"INKT","form_type":"8-K","filed_at":"2025-12-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"MiNK Therapeutics Q3 net loss $2.9M; durable remissions with agenT-797, cash runway through 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $2.9M ($0.65/share) in Q3 2025 vs $1.8M ($0.46) in Q3 2024.","Cash $14.3M at quarter-end; raised $1.2M post-quarter; runway extended through 2026.","Clinical data: durable complete remissions >2 years in refractory cancers; no Grade 3+ CRS/neurotoxicity.","Launching Phase 1 GvHD study with UW-Madison, funded by NIH and philanthropy.","Appointed Dr. Terese Hammond as Head of Inflammatory and Pulmonary Diseases, Dr. Holcomb to Board."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":56843466.67092338,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":142925,"accession_number":"0001193125-25-221863","cik":1840229,"company_name":"MiNK Therapeutics, Inc.","ticker":"INKT","form_type":"8-K","filed_at":"2025-09-29T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"MiNK Therapeutics appoints trauma expert Col. (Ret.) John Holcomb to Board","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. John Holcomb elected as Class II director; term expires at 2026 annual meeting.","Option granted for 4,174 shares vesting over three years under 2021 Equity Plan.","Holcomb served 23 years in U.S. Army, pioneered combat casualty care; 780+ publications.","Appointment aims to advance iNKT therapies into immune-mediated disease and pulmonary disorders."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":56843466.67092338,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":142924,"accession_number":"0001171843-25-005405","cik":1840229,"company_name":"MiNK Therapeutics, Inc.","ticker":"INKT","form_type":"8-K","filed_at":"2025-08-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"MiNK Therapeutics Q2 2025 net loss $4.2M; extends runway with $13M raise; GvHD grants awarded","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash at Q2 end $1.6M; raised $13M post-quarter; runway extended beyond mid-2026.","Net loss Q2 2025 $4.2M ($1.06/shr) vs $2.7M ($0.73/shr) in Q2 2024.","Durable complete remission in metastatic testicular cancer published; patient disease-free >2 years.","DOD STTR grant and new clinical grant awarded for iNKT cell therapy in GvHD; trial target 2H2025.","Phase 2 gastric cancer trial of agenT-797 expects additional readouts in 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.76,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":56843466.67092338,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":142923,"accession_number":"0001193125-25-159017","cik":1840229,"company_name":"MiNK Therapeutics, Inc.","ticker":"INKT","form_type":"8-K","filed_at":"2025-07-15T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"MiNK Therapeutics enters $50M ATM equity offering agreement with B. Riley Securities","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Maximum aggregate offering price of $50M in common stock to be sold at market prices.","Sales agent is B. Riley Securities, Inc.; shares issued via existing Form S-3 registration statement.","Agreement dated July 15, 2025; no minimum sales amount required."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":56843466.67092338,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":142922,"accession_number":"0000950170-25-095460","cik":1840229,"company_name":"MiNK Therapeutics, Inc.","ticker":"INKT","form_type":"8-K","filed_at":"2025-07-14T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"MiNK Therapeutics announces complete remission in testicular cancer and Phase 2 gastric cancer survival data","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Complete and durable remission in metastatic testicular cancer patient after single infusion of agenT-797 plus nivolumab, per Nature's Oncogene publication.","Phase 2 gastric cancer trial data showed immune activation, tumor infiltration, and survival beyond 12 months in checkpoint-refractory patients.","Separate case report: 42% tumor reduction and >9 months progression-free survival in gastric cancer patient with single agenT-797 infusion plus nivolumab.","Phase 2 trial (NCT06251973) actively enrolling with additional readouts expected."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":56843466.67092338,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":161005,"accession_number":"0000950170-25-087888","cik":1840229,"company_name":"MiNK Therapeutics, Inc.","ticker":"INKT","form_type":"8-K","filed_at":"2025-06-18T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"MiNK Therapeutics stockholders elect directors, approve option exchange, ratify KPMG at 2025 annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Jennifer Buell and Ulf Wiinberg elected as Class I directors with 2,337,073 and 2,312,077 votes For, respectively.","Option exchange proposal approved: 2,269,364 For, 97,538 Against, 1,317 Abstain, 424,803 broker non-votes.","Ratification of KPMG LLP as auditor for FY2025: 2,773,188 For, 12,846 Against, 6,988 Abstain."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.15,"market_cap_usd":56843466.67092338,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":161004,"accession_number":"0001171843-25-003207","cik":1840229,"company_name":"MiNK Therapeutics, Inc.","ticker":"INKT","form_type":"8-K","filed_at":"2025-05-15T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"MiNK Therapeutics reports Q1 net loss of $2.8M; cash burn down; clinical progress in iNKT platform","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $2.8M ($0.70/sh) vs $3.8M ($1.10/sh) YoY; cash used in ops down to $1.3M from $2.5M.","Cash balance of $3.2M at March 31, 2025; company pursuing near-term capital transactions to bolster liquidity.","Phase 2 gastric trial (NCT06251973) enrolling; new data shows agenT-797 activity in PD-1-resistant gastroesophageal cancers.","Complete remission in metastatic testicular cancer after single agenT-797 infusion without lymphodepletion or toxicity.","Selected for probable NIAID funding for GvHD program; strategic discussions underway across oncology and immunology."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.7,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":56843466.67092338,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":179199,"accession_number":"0001171843-25-001513","cik":1840229,"company_name":"MiNK Therapeutics, Inc.","ticker":"INKT","form_type":"8-K","filed_at":"2025-03-18T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"MiNK Therapeutics reports FY2024 net loss of $10.8M, improved from $22.5M in 2023","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss for FY2024 was $10.8M ($2.86/diluted share) vs $22.5M ($6.54/share) in 2023.","Cash and cash equivalents at Dec 31, 2024 were $4.6M, up from $3.4M at year-end 2023.","Cash used in operations for FY2024 was $9.6M, compared to $15.8M in 2023.","Clinical progress: AgenT-797 Phase 2 gastric cancer trial enrolling; ARDS data showed ~80% survival in VV ECMO patients.","Raised $5.8M in private financing in 2024; collaboration with Autonomous Therapeutics for RNA-iNKT therapies."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":56843466.67092338,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":179198,"accession_number":"0001193125-25-009595","cik":1840229,"company_name":"MiNK Therapeutics, Inc.","ticker":"INKT","form_type":"8-K","filed_at":"2025-01-21T23:59:59+00:00","items":["5.03","5.07","9.01"],"status":"ready","headline":"MiNK Therapeutics stockholders approve 1-for-10 reverse stock split effective Jan 28","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Special meeting held Jan 17, 2025; 27,582,512 shares voted (quorum).","Proposal approved with 26,500,274 For, 1,026,255 Against, 56,013 Abstain.","Reverse split ratio 1-for-10, effective 12:01 a.m. ET on Jan 28, 2025.","Post-split shares trade under new CUSIP 603693 201 on Nasdaq.","39,630,402 shares outstanding pre-split as of record date Dec 16, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":56843466.67092338,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":195886,"accession_number":"0001171843-24-006360","cik":1840229,"company_name":"MiNK Therapeutics, Inc.","ticker":"INKT","form_type":"8-K","filed_at":"2024-11-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"MiNK Therapeutics Q3 2024 net loss narrows to $1.8M; cash at $6.3M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $1.8M ($0.05 per share) improved from $5.1M ($0.15) in Q3 2023.","Cash and equivalents $6.3M; operations used $3.0M in Q3, down from $4.2M YoY.","R&D expenses fell to $541K from $3.4M; total operating loss $1.9M vs $5.2M.","Phase 2 gastric cancer trial data expected at a major conference in early 2025.","Dr. Robert Kadlec joined board; new collaboration with Autonomous Therapeutics."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.22,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":56843466.67092338,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":195885,"accession_number":"0000950170-24-119270","cik":1840229,"company_name":"MiNK Therapeutics, Inc.","ticker":"INKT","form_type":"8-K","filed_at":"2024-10-31T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"MiNK appoints former HHS ASPR Robert Kadlec to board","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Robert Kadlec elected Class II director effective Oct. 30, 2024; term expires at 2026 annual meeting.","Previously served as HHS Assistant Secretary for Preparedness and Response and co-conceived Operation Warp Speed.","Will serve on Corporate Governance and Nominating Committee; granted option for 41,745 shares vesting over 3 years.","Expertise in biodefense and pandemic preparedness aligns with MiNK's iNKT cell therapy focus on ARDS and infectious diseases."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":56843466.67092338,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":195884,"accession_number":"0000950170-24-115596","cik":1840229,"company_name":"MiNK Therapeutics, Inc.","ticker":"INKT","form_type":"8-K","filed_at":"2024-10-18T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"MiNK Therapeutics CSO Marc Van Dijk transitions to advisory roles effective Nov 15","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Marc Van Dijk leaves Chief Scientific Officer role, becomes Scientific Advisory Board Member and Strategic Consultant.","Transition effective November 15, 2024; Van Dijk to continue supporting programs and collaborations.","No replacement for CSO announced; advisory roles indicate retained expertise."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":56843466.67092338,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":212162,"accession_number":"0000950170-24-106345","cik":1840229,"company_name":"MiNK Therapeutics, Inc.","ticker":"INKT","form_type":"8-K","filed_at":"2024-09-13T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"MiNK Therapeutics receives Nasdaq MVLS deficiency notice; has until March 12, 2025 to comply","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received Nasdaq letter on September 13, 2024 for failing MVLS (minimum value of listed securities) requirement.","MVLS was below $35 million for 30 consecutive trading days, violating Nasdaq Listing Rule 5550(b)(2).","Company has 180 calendar days, until March 12, 2025, to regain compliance.","To comply, MVLS must be $35M or more for at least 10 consecutive trading days.","Failure to cure may lead to delisting; company may then appeal to a Hearings Panel."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":56843466.67092338,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":212161,"accession_number":"0000950170-24-102321","cik":1840229,"company_name":"MiNK Therapeutics, Inc.","ticker":"INKT","form_type":"8-K","filed_at":"2024-08-30T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"MiNK Therapeutics receives Nasdaq delisting notice for failing to meet $1.00 bid price rule","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq notified MiNK on Aug 27, 2024 that it failed to regain compliance with the $1.00 minimum bid price within the 180-day grace period ending Aug 26, 2024.","Common stock (INKT) is now subject to potential delisting from Nasdaq.","MiNK intends to request a hearing before the Nasdaq Hearings Panel, which will stay any delisting action pending the process.","No assurance that the Panel will allow continued listing or that compliance can be demonstrated within any extension granted."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":56843466.67092338,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":212160,"accession_number":"0001171843-24-004721","cik":1840229,"company_name":"MiNK Therapeutics, Inc.","ticker":"INKT","form_type":"8-K","filed_at":"2024-08-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"MiNK Q2 net loss narrows to $2.7M; cash $9.3M; clinical programs advance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss Q2 2024 $2.7M ($0.07/sh) vs $6.2M ($0.18/sh) Q2 2023; 6-month loss $6.5M vs $11.9M.","Cash $9.3M at Jun 30, up from $3.4M at Dec 31; cash used in ops $2.3M for Q2, reduced from $4.2M YoY.","Closed $5.8M PIPE at 25% premium to new investor; cash runway extended into 2025.","AgenT-797: Phase 2 gastric cancer advancing, early data at upcoming conference; Phase 1 GvHD activation planned; ARDS expanded access shows clinical benefit."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.18,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":56843466.67092338,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":231057,"accession_number":"0000950170-24-074233","cik":1840229,"company_name":"MiNK Therapeutics, Inc.","ticker":"INKT","form_type":"8-K","filed_at":"2024-06-17T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"MiNK Therapeutics stockholders elect directors, ratify KPMG at 2024 annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Annual meeting held June 12, 2024; 28,359,271 shares (81.71%) present or represented.","Brian Corvese and Peter Behner elected as Class III directors for three-year terms.","Ratification of KPMG LLP as independent auditor for FY2024 approved with 28,242,636 votes for.","Broker non-votes of 3,364,923 on director elections and none on auditor ratification."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":56843466.67092338,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":231056,"accession_number":"0000950170-24-060805","cik":1840229,"company_name":"MiNK Therapeutics, Inc.","ticker":"INKT","form_type":"8-K","filed_at":"2024-05-16T23:59:59+00:00","items":["1.01","3.02"],"status":"ready","headline":"MiNK Therapeutics raises ~$5.8M via 4.64M shares at $1.25/share, 25% premium to VWAP","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Issued 4,640,000 common shares at $1.25 per share, a 25% premium to 30-day VWAP.","Net proceeds of approximately $5.8 million after offering expenses.","Transaction closed on May 14, 2024.","Registration statement due by Aug 15, 2024; investor locked up until Nov 9, 2024.","Investor agrees to vote shares in line with board recommendation through May 14, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":56843466.67092338,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":231055,"accession_number":"0001171843-24-002826","cik":1840229,"company_name":"MiNK Therapeutics, Inc.","ticker":"INKT","form_type":"8-K","filed_at":"2024-05-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"MiNK Q1 net loss narrows to $3.8M; $5.8M PIPE to fund MiNK-215 IND in 2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $3.8M ($0.11 per share) vs $5.7M ($0.17) YoY; cash used in ops $2.5M.","Quarter-end cash $5.8M; closed $5.8M PIPE at 25% premium with new investor.","Phase 2 trial of agenT-797 in gastroesophageal cancers actively enrolling; initial results expected H2 2024.","MiNK-215 eliminated MSS colorectal cancer liver metastases in human organoid models (AACR data).","Upcoming ATS presentation (May 21) on agenT-797 in severe respiratory distress in a renal transplant patient."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.11,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":56843466.67092338,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":249460,"accession_number":"0001171843-24-001514","cik":1840229,"company_name":"MiNK Therapeutics, Inc.","ticker":"INKT","form_type":"8-K","filed_at":"2024-03-21T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"MiNK Therapeutics reports FY2023 net loss $22.5M; cash $3.4M at year-end","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss for 2023 was $22.5M ($0.65/share) vs. $28.0M ($0.83/share) in 2022.","Cash and cash equivalents $3.4M at Dec 31, 2023; received $5M post-year-end from Agenus convertible note.","Launched Phase 2 trial of agenT-797 with botensilimab/balstilimab/chemo in 2L gastroesophageal cancers.","Entered collaboration with Immunoscape to develop TCR-based therapies against novel targets.","Nature Communications publication showed >70% survival in ARDS patients on mechanical ventilation with agenT-797."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":56843466.67092338,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":249459,"accession_number":"0000950170-24-023061","cik":1840229,"company_name":"MiNK Therapeutics, Inc.","ticker":"INKT","form_type":"8-K","filed_at":"2024-02-29T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"MiNK receives Nasdaq deficiency notices for MVLS and minimum bid price; faces potential delisting","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["On Feb 23, 2024, Nasdaq notified MiNK that its MVLS was below $35M for 30 consecutive days; compliance deadline Aug 21, 2024.","On Feb 26, 2024, Nasdaq notified MiNK that its common stock bid price closed below $1.00 for 30 consecutive days; deadline Aug 26, 2024.","To regain MVLS compliance, MVLS must be ≥$35M for 10 consecutive days; failure may lead to delisting with appeal rights.","To regain bid price compliance, stock must close at ≥$1.00 for 10 consecutive days; possible additional 180-day cure period if eligible.","MiNK is evaluating options to regain compliance but provides no assurance of success."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":56843466.67092338,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":249458,"accession_number":"0000950170-24-014944","cik":1840229,"company_name":"MiNK Therapeutics, Inc.","ticker":"INKT","form_type":"8-K","filed_at":"2024-02-14T23:59:59+00:00","items":["1.01","2.03"],"status":"ready","headline":"MiNK Therapeutics issues up to $5.0M convertible promissory note to Agenus at 2% interest","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Principal amount up to $5.0M; interest rate 2% per annum, accruing but payable upon conversion or maturity.","Demand repayment on or after Jan 1, 2026; optional conversion into equity upon qualified financing at Agenus's election.","Funds may be drawn in increments with Agenus's consent; advances may include payments made by Agenus on Company's behalf."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":56843466.67092338,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":266907,"accession_number":"0001171843-23-006910","cik":1840229,"company_name":"MiNK Therapeutics, Inc.","ticker":"INKT","form_type":"8-K","filed_at":"2023-11-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"MiNK Therapeutics Q3 net loss $5.1M; cash $6.4M; agenT-797 shows durable solid tumor benefit","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash $6.4M at Sep 30, 2023, down from $19.6M at Dec 31, 2022; Q3 cash used in ops $4.2M.","Q3 net loss $5.1M ($0.15/sh); 9-month net loss $17M ($0.50/sh), vs $20.2M ($0.60/sh) year ago.","AgenT-797: >30% disease stabilization/biomarker response in heavily pretreated solid tumors; durable gastric cancer response.","Randomized Phase 2 trial of agenT-797 in 2L gastric cancer to launch this year, externally funded, led by MSKCC.","R&D expense down to $3.4M ($6.2M in Q3 2022) as company focuses iNKT platform and cGMP manufacturing."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.5,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":56843466.67092338,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":266906,"accession_number":"0000950170-23-053752","cik":1840229,"company_name":"MiNK Therapeutics, Inc.","ticker":"INKT","form_type":"8-K","filed_at":"2023-10-17T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"MiNK Therapeutics director Dr. John Baldoni resigns effective Oct 31, 2023","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. John Baldoni resigns from board effective Oct 31, 2023, citing manufacturing advancements reducing need for his technical contributions.","He will serve as ad hoc technical advisor to the Company following his departure.","Baldoni did not step down due to any disagreement with MiNK's operations, policies, or practices.","Notice of resignation was sent on October 12, 2023; effective October 31, 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":56843466.67092338,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":284190,"accession_number":"0001171843-23-005189","cik":1840229,"company_name":"MiNK Therapeutics, Inc.","ticker":"INKT","form_type":"8-K","filed_at":"2023-08-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"MiNK reports Q2 2023 net loss $6.2M; cash low at $10.6M; Phase 2 gastric trial planned","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Six-month 2023 net loss $11.9M ($0.35/share) vs $13.9M ($0.41) in prior year period.","Cash $10.6M at June 30, 2023, down from $14.9M at March 31, 2023; Q2 cash used $4.1M.","Externally funded randomized Phase 2 trial in 2L gastric cancer planned at MSKCC; IND for MiNK-215 on track for 2024.","AgenT-797 showed 75% survival in COVID-19 ARDS patients vs 30% in-hospital controls; dosed up to 1B cells."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.35,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":56843466.67092338,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":303815,"accession_number":"0000950170-23-028900","cik":1840229,"company_name":"MiNK Therapeutics, Inc.","ticker":"INKT","form_type":"8-K","filed_at":"2023-06-20T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"MiNK Therapeutics stockholders elect Garo Armen and Barbara Ryan as Class II directors, ratify KPMG as auditor","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Garo Armen received 29,157,446 for and 282,326 withheld; Barbara Ryan 29,193,530 for and 246,242 withheld.","KPMG LLP ratified as independent auditor for FY2023 with 30,644,494 for, 5,764 against, 110,413 abstentions.","Quorum of 30,760,671 shares (89.6% of outstanding) present at June 13, 2023 Annual Meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":56843466.67092338,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":303814,"accession_number":"0001171843-23-003188","cik":1840229,"company_name":"MiNK Therapeutics, Inc.","ticker":"INKT","form_type":"8-K","filed_at":"2023-05-11T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"MiNK Therapeutics Q1 net loss $5.7M; agenT-797 shows durable responses in solid tumors","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $5.7M ($0.17/share) vs $7.8M ($0.23) in Q1 2022; cash $14.9M at March 31, 2023.","agenT-797 + anti-PD-1 achieved 42% tumor reduction in metastatic gastric cancer lasting >9 months; durable disease stabilization in anti-PD-1 refractory NSCLC.","Initiating phase 1/2 expansion studies in NSCLC and gastric cancer; majority costs planned for external non-dilutive grant funding.","Upcoming presentations: FAP-CAR-iNKT at ASGCT May 19; agenT-797 in viral ARDS at ATS May 21.","Manufacturing capacity 5,000 doses/year, rapidly expanding."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.17,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":56843466.67092338,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":323506,"accession_number":"0001171843-23-001783","cik":1840229,"company_name":"MiNK Therapeutics, Inc.","ticker":"INKT","form_type":"8-K","filed_at":"2023-03-21T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"MiNK Therapeutics reports Q4 net loss $7.8M; cash $19.6M at Dec 31, 2022","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss for Q4 2022: $7.8M ($0.23/share) vs $5.8M ($0.18) in Q4 2021.","Full year 2022 net loss $28.0M ($0.83/share) vs $30.2M ($1.16) in 2021.","Cash and equivalents $19.6M at Dec 31, 2022, down from $38.9M at Dec 31, 2021.","Cash used in operations FY2022 $18.9M; R&D expense rose to $23.1M from $14.0M.","Clinical update for agenT-797 in solid tumors to be presented at AACR April 2023; expansion into NSCLC/gastric cancer in 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":56843466.67092338,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":341531,"accession_number":"0001171843-22-007046","cik":1840229,"company_name":"MiNK Therapeutics, Inc.","ticker":"INKT","form_type":"8-K","filed_at":"2022-11-03T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"MiNK Therapeutics Q3 2022 net loss $6.3M, cash $24.2M; pipeline and R&D day updates","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $6.3M ($0.19/share) in Q3 2022 vs $14.3M ($0.59/share) in Q3 2021; nine-month loss $20.2M.","Cash $24.2M at Sep 30, 2022, down from $38.9M at Dec 31, 2021; cash used in ops $14.4M in nine months.","Five abstracts accepted at SITC 2022; R&D day Nov 10, 2022 featuring external experts.","R&D expenses rose to $6.15M from $3.33M in Q3 2021 due to internal cGMP manufacturing scale-up.","No revenue or guidance; clinical-stage biotech advancing allogeneic iNKT cell therapies."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.6,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2022-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":56843466.67092338,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":358471,"accession_number":"0001171843-22-005501","cik":1840229,"company_name":"MiNK Therapeutics, Inc.","ticker":"INKT","form_type":"8-K","filed_at":"2022-08-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"MiNK Q2 net loss $6.1M; cash $29.8M; DARPA selects AgenT-797; clinical data updates expected 2H22","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash $29.8M as of June 30, 2022, down from $38.9M at Dec 31, 2021; cash used in ops $4.6M for Q2.","Net loss $6.1M ($0.18/share) vs $6.3M ($0.26/share) in Q2 2021; R&D spend $5.9M vs $3.6M.","AgenT-797 clinical data updates in solid tumors, myeloma and viral ARDS planned for 2H2022.","AgenT-797 identified as selectable for DARPA funding; contract negotiations underway.","Internal cGMP manufacturing completed with capacity to treat >700,000 patients/year; Dr. Joy Zhou appointed VP CMC."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.41,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2022-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":56843466.67092338,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":358470,"accession_number":"0001193125-22-213655","cik":1840229,"company_name":"MiNK Therapeutics, Inc.","ticker":"INKT","form_type":"8-K","filed_at":"2022-08-05T23:59:59+00:00","items":["1.01"],"status":"ready","headline":"MiNK Therapeutics enters amended intercompany services agreement with Agenus effective April 1, 2022","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["New agreement covers G&A, R&D, and shared services; MiNK pays 10% of Agenus' G&A costs.","R&D services charged at pass-through costs plus allocation of employee costs.","Shared services no charge if proportional; facility/insurance use with proportionate payment.","Either party may terminate with 60 days' notice; individual services 30 days.","Agreement retroactive to April 1, 2022, amends September 2021 agreement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":56843466.67092338,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":377238,"accession_number":"0001193125-22-173902","cik":1840229,"company_name":"MiNK Therapeutics, Inc.","ticker":"INKT","form_type":"8-K","filed_at":"2022-06-14T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"MiNK adopts Executive Change of Control Plan; stockholders elect directors, ratify KPMG","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board approved Executive Change of Control Plan providing 50% time-based equity vesting upon a change of control.","Plan includes severance: 12 months salary plus target/actual bonus, COBRA coverage, and full equity vesting for qualifying terminations after a change of control.","Stockholders re-elected Peter Behner, Jennifer Buell, and Ulf Wiinberg as Class I directors at June 8 annual meeting.","Proposal to ratify KPMG as independent auditor for FY2022 approved with 28.1M votes for.","Plan also includes non-compete and non-solicitation covenants for participating executives."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":56843466.67092338,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":377237,"accession_number":"0001171843-22-003482","cik":1840229,"company_name":"MiNK Therapeutics, Inc.","ticker":"INKT","form_type":"8-K","filed_at":"2022-05-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"MiNK Q1 2022 net loss $7.8M ($0.23/share); cash $34.7M; clinical milestones on track","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $7.8M vs $3.8M YoY; per share loss $0.23 vs $0.16; non-cash expenses $813K.","Cash balance $34.7M at March 31, 2022; projected FY 2022 cash burn $16.8M.","R&D expenses $5.3M (+70% YoY) and G&A $2.1M (+253% YoY) due to increased activity.","Clinical data readouts for agenT-797 in solid tumors and ARDS on track for 2H 2022.","GMP manufacturing launch anticipated in 1H 2022 with target 10,000 doses/yr."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.23,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":56843466.67092338,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":395616,"accession_number":"0001193125-22-069441","cik":1840229,"company_name":"MiNK Therapeutics, Inc.","ticker":"INKT","form_type":"8-K","filed_at":"2022-03-08T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"MiNK Therapeutics finalizes employment agreements for CEO ($425k) and CSO (£260k)","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["CEO Dr. Buell: $425,000 base salary, 50% bonus target, compensation retroactive to Jan 1, 2022.","CSO Dr. van Dijk: £260,000 base salary, £18,000 housing/travel budget, 35% bonus target.","Without cause termination: Buell receives 12 months salary, bonus, COBRA, and $15k outplacement.","Change-in-control: Buell gets 18 months salary plus 150% bonus, full vesting acceleration of equity."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":56843466.67092338,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":395615,"accession_number":"0001193125-22-003536","cik":1840229,"company_name":"MiNK Therapeutics, Inc.","ticker":"INKT","form_type":"8-K","filed_at":"2022-01-06T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"MiNK Therapeutics board member Dr. Walter Flamenbaum retires as planned","summary_kind":"llm","event_type":"leadership","confidence":"medium","bullets":["Dr. Walter Flamenbaum retired from the Board of Directors effective December 31, 2021.","His retirement was previously disclosed in the Company's Amended Registration Statement filed on October 12, 2021.","No immediate replacement was announced; the departure was part of a previously planned transition."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":56843466.67092338,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":414406,"accession_number":"0001193125-21-303045","cik":1840229,"company_name":"MiNK Therapeutics, Inc.","ticker":"INKT","form_type":"8-K","filed_at":"2021-10-20T23:59:59+00:00","items":["3.03","5.03","9.01"],"status":"ready","headline":"MiNK Therapeutics files amended charter post-IPO, authorizing 150M common and 5M preferred shares","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Amended charter and bylaws became effective upon IPO closing on October 19, 2021.","Authorized capital: 150,000,000 shares of common stock, par value $0.00001 per share.","Authorized capital includes 5,000,000 shares of preferred stock.","Charter and bylaws are in the form previously filed with the Registration Statement on Form S-1.","No other material modifications to security holder rights were reported."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":56843466.67092338,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}